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For the most part, publishing of re-
search is a gratifying experience for
journals and authors. Such publishing is
predicated, above all, on trust. Authors
need to trust that a journal’s reviewers and
editors provide a fair review process of
their papers. And of course journals need
to trust authors to provide a fair, honest,
and complete account of their work. Only
then can readers have trust in the articles
that are published.
Looking back over the past year at
PLoS, as well as across the broader
landscape of academic publishing, it would
be hard to conclude that this trusting
relationship has not been shaken rather
profoundly at times. Editors have some-
times been taken unawares by ghost and
guest authors, manipulation of figures,
lack of authors’ willingness to share data,
failure to register trials, and salami-slicing
of data to produce the ‘‘least publishable
unit.’’ From an author’s perspective—
reflected in our survey of authors earlier
this year, for example—the relationship
may not have been as rosy as it should
have been. Long decision times, hyper-
critical reviewers, seemingly impossible
demands at the production stage, and
rejection after an extended review process
are always hard for authors to bear.
So in the spirit of a soon-to-be New
Year we’d like to gently offer some
suggestions for resolutions for all authors,
reviewers, readers, and editors to ponder.
We hope that no one will take offence and
trust that our choices will become clear as
we explain.
For authors…
N My authorship list will be complete and
accurate, and everyone named will deserve
authorship; in particular there will be no ghost
or guest authors.
In case anyone doubts that such a
resolution is necessary, look at the furor
in July 2009 about the involvement of
ghost authors in Wyeth’s marketing of
Prempro that came to light after our
intervention, with TheNewYork Times,i n
a courtcase [1].Closertohome, a study
presented at the Sixth International
Congress on Peer Review in September
2009 suggested that we at PLoS Medicine
have both guest and ghost authors
lurking in our papers [2].
N I’ll have all the data to back up my paper and its
images, and none of it will have been
manipulated to look prettier than it really was
when it came off the scanner/computer.
Unfortunately, many authors are un-
able to provide the original data
underpinning their studies and images.
For example, a preliminary survey by
PLoS Biology and PLoS Medicine in 2009
found that 15% of all authors who
have been asked for original data could
not find it. We don’t yet know how
often, say, a misplaced gel means
manipulation of data, but being fooled
even once would be too often, so we
will continue to routinely check all
images on accepted papers.
N I’ll stand by my agreement to share all the data
that underpins my research [3]. As part of that
commitment I will share the study protocol for that
research, when requested by editors.
At PLoS Medicine, we consider the
minimization of reporting biases an
important part of our role, and duly
require authors submitting reports of
clinical trials to also provide a copy of
the prespecified study protocol. We
have on occasion had our requests for
protocols met with the response ‘‘How
would you like the document written?’’
Can it surprise anyone that such a
response shakes our confidence in the
prespecified nature of the analyses?
N I’ll make sure I’ve complied with all the
requirements for trial registration.
Trials are still submitted to us that have
not been registered. Compulsory trial
registration has been in place for more
than three years now, and it is clearly laid
out in our author guidelines [4] We
therefore will reject unregistered trial
reports. And while we’re on the subject
of registration, why not register all human
subjects research? An increasing number
of researchers are doing so in Clinical-
Trials.gov, and there are compelling
reasons for expanding such registration.
For reviewers…
N If I’m unable to review a paper, I’ll let the
editor know within a few days of
receiving the request to review.
Editors expect reviewers to say ‘‘no’’ to
requests quite often—we understand
you are busy. But if you can let us
know quickly, we can then provide
authors with a faster editorial peer
review process. We also expect review-
ers to declare competing interests
related to the paper or the authors [5].
N If I promise to review I will do so.
Late reviews cause even more prob-
lems than late responses to review
requests. Not only does failure to
provide a timely review set the evalu-
ation process back, but reviews that
never materialize also raise questions
about a reviewer’s motives for agreeing
to review in the first place.
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The tone of a review can mar an
otherwise very helpful review. Reviews
also aren’t the place to impugn the
authors’ motives, unless of course you
have incontrovertible evidence. Even
so, it is best to stick to the facts. We’ll
take it very seriously if you contact us
to say that there is something we must
scrutinize further.
For our readers…
N Will you resolve to talk to us?
We’d urge our readers to tell us more
about what you want from the journal
and its online functionality, and what
you think of the articles themselves.
Read, rate, and reuse the papers.
Open access journals are only partially
fulfilling their mission if the papers
they publish remain embedded in the
journals they were originally published
in and not reused or redistributed.
And, finally, for editors…
We’re sure our authors will have
opinions on this but here’s what we resolve
to do.
N We’ll be quick, efficient, and courteous in our
process.
We understand how important your
work is. We have all been authors too.
Presubmission inquiries have been
successful in reducing our first decision
time to about 24 hours. We are now
actively looking at all aspects of our
process to decrease time to decisions
later in the process.
N We’ll review the composition of our editorial
and reviewer boards in an attempt to be
inclusive in the people we get to advise
us.
N We’ll listen to our authors and reviewers if
they have complaints or suggestions.
So please, if we send you a survey, fill it
in. We love feedback, even if it’s not
positive.
N We’ll continue to advocate for the highest level
of publishing ethics.
We will continue to publish editors’
competing interests [6] and abide by
the editors’ code of conduct developed
by the Committee on Publication
Ethics (COPE) [7].
N We’ll continue to innovate.
We recognize there is still a ways to go
before open access journals fulfill the
promise of a truly integrated informa-
tion resource. So far this year we have
instituted new ways of publishing by
using our new TOPAZ software pro-
gram, which provides enhanced ability
to comment on articles. The recently
launched article level metrics on all the
PLoS journals [8] now provide new
ways of assessing the true impact of
papers. But we recognize the need to
do more.
Here’s one more resolution we’d like to
share with everyone. By the time this
editorial is published, leaders representing
signatories to the United Nations Frame-
work Convention on Climate Change will
have met in Copenhagen. Whatever the
outcome of the summit, the solution to
climate change can’t just rest with politi-
cians – it is the responsibility of us all.
We’ve just signed up to 10:10 [9] (we
commit to cutting 10% of our carbon
emissions in 2010) and we’d encourage
everyone to do the same. In addition to
being an important practical action, it also
shows a collective will toward constructive
change, something that our authors,
reviewers, and readers have already shown
in their support of open access. We’ll be
writing more about this in 2010. Between
now and then have a very a happy and
peaceful New Year, and if you can find
time between the celebrations, write and
tell us your resolutions.
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